RESECT Study Results and Variations in NMIBC Recurrence Between Sites
The ongoing RESECT study began in 2021 to determine if audit and feedback could improve the quality of transurethral resection of bladder tumor (TURBT) in the treatment of non-muscle invasive bladder cancer (NMIBC) to see if it may lead to reduced disease recurrence. A new observational study sought to determine if there is significant variation in early recurrence after TURBT between the sites taking part in the RESECT study. The results will be presented at the American Society of Clinical Oncology 2023 Annual Meeting. ...
Advertisement
Advertisement

Latest News

Advertisement
Advertisement
Editorial Advisory Board

Expert Interviews

Knowledge Hubs

Curated clinical content based on conditions, therapies, and technologies

Prostate Cancer
Prostate Cancer

The Uromigos

Podcasts hosted by Professors Thomas Powles, MD, and Brian Rini, MD

Conference Coverage

Live meeting highlights

Emily MenendezASCO 2023 | June 1, 2023
Results of the STARTAR phase 2 trial on salvage RT plus apalutamide and docetaxel were presented at the 2023 ASCO meeting.
Read More
Emily MenendezASCO 2023 | June 1, 2023
The PROOF 302 trial examined the efficacy and safety of infigratinib against placebo in patients with high-risk invasive UC.
Emily MenendezASCO 2023 | June 1, 2023
A post-hoc exploratory analysis of the KEYNOTE-361 study was presented at the 2023 ASCO annual meeting.
Emily MenendezASCO 2023 | May 31, 2023
Questions from the surveys were rated as relevant or nonrelevant by patients with RCC.

Video Insights

Clinical discussions with experts in the field